Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Champions Oncolog (CSBR)

Champions Oncolog (CSBR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,270
  • Shares Outstanding, K 13,559
  • Annual Sales, $ 49,110 K
  • Annual Income, $ 550 K
  • 60-Month Beta 0.96
  • Price/Sales 1.13
  • Price/Cash Flow 25.55
  • Price/Book 6.06
Trade CSBR with:

Options Overview Details

View History
  • Implied Volatility 160.08% ( +47.51%)
  • Historical Volatility 102.24%
  • IV Percentile 82%
  • IV Rank 53.55%
  • IV High 298.78% on 12/15/22
  • IV Low 0.20% on 10/11/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 8
  • Put/Call OI Ratio 1.42
  • Today's Open Interest 186
  • Open Int (30-Day) 188

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 01/31/23
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year 0.05
  • Growth Rate Est. (year over year) -220.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.05 +1.98%
on 01/27/23
4.63 -10.80%
on 01/09/23
-0.38 (-8.43%)
since 12/30/22
3-Month
3.75 +10.13%
on 12/20/22
7.24 -42.95%
on 11/23/22
-2.81 (-40.49%)
since 10/31/22
52-Week
3.75 +10.13%
on 12/20/22
9.88 -58.20%
on 08/09/22
-3.67 (-47.05%)
since 01/28/22

Most Recent Stories

More News
Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 7.30% and 9.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

ENTA : 52.74 (+3.51%)
CSBR : 4.11 (-0.96%)
MediWound (MDWD) Reports Q3 Loss, Tops Revenue Estimates

MediWound (MDWD) delivered earnings and revenue surprises of -30% and 24.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MDWD : 13.80 (+0.51%)
CSBR : 4.11 (-0.96%)
Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Lags Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -140% and 91.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

INFI : 0.6250 (+2.27%)
CSBR : 4.11 (-0.96%)
Champions Oncology, Inc. (CSBR) Reports Q1 Loss, Tops Revenue Estimates

Champions Oncology, Inc. (CSBR) delivered earnings and revenue surprises of -300% and 2.27%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

CSBR : 4.11 (-0.96%)
ISR : 0.3699 (+12.09%)
Champions Oncology Reports Quarterly Revenue of $12.9 Million

Record Annual Revenue of $49.1 Million

CSBR : 4.11 (-0.96%)
Champions Oncology to Announce Fourth Quarter Financial Results on Thursday, July 21, 2022

HACKENSACK, NJ / ACCESSWIRE / July 14, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic...

CSBR : 4.11 (-0.96%)
Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics

HACKENSACK, NJ and TORONTO, ON / ACCESSWIRE / May 31, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven...

CSBR : 4.11 (-0.96%)
Champions Oncology Announces its Lumin Bioinformatics Platform Selected as a Finalist for the 'Best in Show' Competition at Bio-IT World Conference & Expo

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

CSBR : 4.11 (-0.96%)
Has Champions Oncology, Inc. (CSBR) Outpaced Other Medical Stocks This Year?

Here is how Champions Oncology, Inc. (CSBR) and Gamida Cell (GMDA) have performed compared to their sector so far this year.

CSBR : 4.11 (-0.96%)
GMDA : 1.5800 (+0.63%)
Champions Oncology Reports Record Quarterly Revenue of $13.2 Million Reported Adjusted EBITDA of $1.5 million

HACKENSACK, NJ / ACCESSWIRE / March 15, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic...

CSBR : 4.11 (-0.96%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Champions Oncology, Inc., formerly known as Champions Biotechnology, Inc., engages in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company's Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the...

See More

Key Turning Points

3rd Resistance Point 4.23
2nd Resistance Point 4.20
1st Resistance Point 4.17
Last Price 4.11
1st Support Level 4.11
2nd Support Level 4.08
3rd Support Level 4.05

See More

52-Week High 9.88
Fibonacci 61.8% 7.54
Fibonacci 50% 6.82
Fibonacci 38.2% 6.09
Last Price 4.11
52-Week Low 3.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar